Beijing Tiantan Biological Products Co., Ltd. Beijing Tiantan Biological Products Co., Ltd.

Beijing Tiantan Biological Products Co., Ltd.

600161

주식 순위 #4320
Beijing Tiantan Biological Products Co., Ltd., established in 1998 and... Beijing Tiantan Biological Products Co., Ltd., established in 1998 and headquartered in Beijing, China, is actively involved in the full spectrum of blood product operations within China. This includes pioneering research and development, manufacturing, sales, and providing consultancy services. Its comprehensive product line features critical blood-derived medicines such as intravenous immunoglobulin, human albumin, and various specialized human immunoglobulins for conditions like hepatitis B (both standard and freeze-dried formulations) and tetanus, alongside other general human immunoglobulin preparations and intravenous blood system solutions. The company operates as a subsidiary of China National Biotec Group Company Limited.
주가
$1.81
시가총액
$3.59B
변동 (1일)
-0.90%
변동 (1년)
-32.39%
국가
CN
거래 Beijing Tiantan Biological Products Co., Ltd. (600161)

카테고리

Healthcare
Beijing Tiantan Biological Products Co., Ltd. (600161)의 매출
Oct 2026 기준 매출 TTM: 0
Beijing Tiantan Biological Products Co., Ltd.의 최신 재무 보고서에 따르면 회사의 현재 수익 (TTM)은 0입니다. 2026년에 회사는 0의 수익을 올렸으며 이는 2026년의 0 대비 동일입니다. 수익은 상품이나 서비스를 판매하여 얻은 총 수입을 의미합니다. 수익과는 달리 비용이 차감되지 않습니다.
Beijing Tiantan Biological Products Co., Ltd.의 수익 기록 (2001 ~ 2026)
매년 말 매출
연도 매출 변화
2025 $877.40M 6.17%
2024 $826.38M 12.92%
2023 $731.85M 18.47%
2022 $617.77M -4.52%
2021 $646.98M 22.66%
2020 $527.44M 11.91%
2019 $471.31M 10.61%
2018 $426.11M 11.64%
2017 $381.67M 23.92%
2016 $308.00M 23.62%
2015 $249.16M -15.51%
2014 $294.89M -2.60%
2013 $302.76M 25.67%
2012 $240.92M 8.92%
2011 $221.19M 21.43%
2010 $182.15M 13.03%
2009 $161.16M 61.08%
2008 $100.05M 37.71%
2007 $72.66M 37.07%
2006 $53.01M 24.61%
2005 $42.54M 21.37%
2004 $35.05M 18.43%
2003 $29.59M 22.68%
2002 $24.12M 28.78%
2001 $18.73M 0.00%
유사 기업 또는 경쟁사의 매출
회사 매출 매출 차이 국가
$12.62B -
US
$2.23B -
US
$15.74B -
AU
$6.02B -
NL
- -
CH